pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›ENOBY
drug
save

ENOBY

Marketedupdated 3mo ago
by $LBRX LB PHARMACEUTICALS INC
Approved
community read0 votes

🐶 often sniffed alongside

top 5
  • tagApproval8 co-mentions · 2 sources
  • companyHikma Pharmaceuticals Plc4 co-mentions · 2 sources
  • companyHikma Pharmaceuticals USA Inc4 co-mentions · 2 sources
  • drugdenosumab4 co-mentions · 2 sources
  • drugXgeva4 co-mentions · 2 sources

all catalysts(2)

approval · 2
Sep 26, 2025
approval
$LBRX47.77+7.92%
11mo ago
ENOBY (DENOSUMAB-QBDE) — FDA approval
ENOBY
→
Oct 29, 2025
approval
$LBRX47.77+7.92%
10mo ago
ENOBY (DENOSUMAB-QBDE) — FDA approval
ENOBY
→

News(0)

no news has mentioned this drug yet

brand
ENOBY
generic
DENOSUMAB-QBDE
MOA
12.1 Mechanism of Action Denosumab products bind to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. Denosumab products prevent RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone.
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 17m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?